Want to see SE:PROGEN full AI Analyst Report?
Top Page
Prostatype Genomics AB
(PROGEN)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.10
▼(-86.67% Downside)
Action:Reiterated
Date:09/29/26
The score is held down primarily by heavy, persistent losses and significant ongoing cash burn, despite some TTM revenue improvement and manageable leverage. Technicals reinforce the risk profile with a clear downtrend (price below key moving averages) and weak momentum indicators. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Revenue Growth
The recent increase in revenue indicates some progress in commercial adoption of the company’s diagnostics offering. If this growth can persist, a larger installed customer base could improve operating leverage and provide a foundation for eventual profitability.
Negative Factors
Persistent Unprofitability
Deeply negative margins show that current test economics are not covering the company’s operating and delivery costs. Unless pricing, utilization, or cost efficiency improves materially, continued losses could limit reinvestment and make the commercial model difficult to scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The recent increase in revenue indicates some progress in commercial adoption of the company’s diagnostics offering. If this growth can persist, a larger installed customer base could improve operating leverage and provide a foundation for eventual profitability.
Read all positive factors
Prostatype Genomics AB (PROGEN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr83.35M
Dividend YieldN/A
Average Volume (3M)10.31M
Price to Earnings (P/E)―
Beta (1Y)-0.43
Revenue Growth143.94%
EPS Growth70.95%
CountrySE
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.55
Shares Outstanding683,160,770
10 Day Avg. Volume6,075,239
30 Day Avg. Volume10,309,686
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr1.23M
Prostatype Genomics AB Business Overview & Revenue Model
Company Description
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason...
How the Company Makes Money
PROGEN primarily makes money by commercializing its prostate cancer prognostic testing offering to healthcare providers and/or clinical laboratories. Revenue is generated when the test is ordered for eligible patients and performed (either by PROG...
Prostatype Genomics AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01M | 594.00K | 199.00K | 1.36M | 683.00K | 10.00K |
| Gross Profit | -27.83M | -37.62M | 1.92M | 3.73M | 683.00K | 2.51M |
| EBITDA | -35.27M | -36.89M | -37.40M | -38.02M | -26.79M | -15.46M |
| Net Income | -37.90M | -44.50M | -41.05M | -41.44M | -29.09M | -15.63M |
Balance Sheet | ||||||
| Total Assets | 39.91M | 50.86M | 41.97M | 49.22M | 30.95M | 40.20M |
| Cash, Cash Equivalents and Short-Term Investments | 392.00K | 9.07M | 9.42M | 2.68M | 11.49M | 20.33M |
| Total Debt | 0.00 | 5.30M | 67.00K | 11.67M | 867.00K | 1.27M |
| Total Liabilities | 33.36M | 24.33M | 8.50M | 24.55M | 4.80M | 4.30M |
| Stockholders Equity | 6.55M | 26.53M | 33.47M | 24.67M | 26.15M | 35.91M |
Cash Flow | ||||||
| Free Cash Flow | -20.96M | -24.06M | -52.57M | -37.70M | -27.69M | -18.58M |
| Operating Cash Flow | -20.90M | -23.80M | -44.71M | -29.14M | -27.69M | -16.08M |
| Investing Cash Flow | -12.27M | -13.36M | -8.36M | -8.57M | 0.00 | -2.50M |
| Financing Cash Flow | 20.64M | 36.83M | 59.75M | 28.91M | 18.85M | 23.05M |
Prostatype Genomics AB Technical Analysis
Negative
0.75
Price Trends
0.14
Negative
0.17
Negative
0.27
Negative
Market Momentum
>-0.01
Positive
33.73
Neutral
13.07
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 0.75 is above the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.14, and above the 200-day MA of 0.27, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 33.73 is Neutral, neither overbought nor oversold. The STOCH value of 13.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.
Prostatype Genomics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr873.20M | 55.54 | ― | ― | 6.51% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr94.04M | -0.83 | -279.07% | ― | 31.66% | 79.68% | |
44 Neutral | kr339.18M | -1.33 | -60.76% | ― | 79.55% | 90.21% | |
43 Neutral | kr225.79M | -5.49 | -100.09% | ― | 65.82% | 41.28% | |
42 Neutral | kr83.35M | -0.19 | -229.18% | ― | 143.94% | 70.95% | |
42 Neutral | kr90.68M | -1.24 | -75.51% | ― | 56.06% | 63.95% |
* Healthcare Sector Average
SE:PROGEN
Prostatype Genomics AB
0.10
-0.11
-51.85%
SE:IMMNOV
Immunovia AB
0.14
-0.25
-63.92%
SE:QLINEA
Q-linea AB
17.60
-9.15
-34.21%
SE:ACARIX
Acarix AB
0.19
-0.11
-38.21%
SE:BIOVIC.B
Biovica International AB Class B
0.31
-0.31
-50.00%
SE:DVYSR
Devyser Diagnostics AB
51.10
-90.70
-63.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.